592542-50-2

Basic information

• Product Name: (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine
• Synonyms: (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine;ON01500;(E)-2′,4′,6′-triMethoxystyryl-4-Methoxy-3-aMinobenzyl sulfone
• CAS NO: 592542-50-2
• Molecular Formula: C₁₉H₂₃NO₆S
• Molecular Weight: 393.45402
• Mol File: 592542-50-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 146-148 °C
• Boiling Point: 661.2±55.0 °C(Predicted)
• Appearance: /
• Density: 1.267±0.06 g/cm3(Predicted)
• PKA: 3.96±0.10(Predicted)
• CAS DataBase Reference: (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine(592542-50-2)
• EPA Substance Registry System: (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine(592542-50-2)

Safety Data

• Hazardous Substances Data: 592542-50-2(Hazardous Substances Data)

Usage

General Description

The chemical compound (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, also known as (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine, is a complex molecule with a sulfone and amine functional groups. It is derived from the aromatic compounds styryl sulfoxides and amines, and possesses methoxy and methyl substituents. (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine has potential applications in medicinal chemistry and organic synthesis due to its unique molecular structure and reactivity. Additionally, it may have biological activities and could be a potential target for pharmaceutical research and drug development.

Upstream product

• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 136612-71-0 (2,4,6-Trimethoxyphenyl)acetylene 
• 830-79-5 2,4,6-trimethoxybenzaldehyde 
• 1330633-87-8 2-(2’,2’-dibromovinyl)-1,3,5-trimethoxybenzene 
• 1330633-86-7 (E)-2',4',6'-trimethoxystyryl-4-methoxy-3-nitrobenzyl sulfide 
• 908344-21-8 3-nitro-4-methoxybenzyl mercaptan 
• 908344-08-1 (E)-2',4',6'-trimethoxystyryl-4-methoxy-3-aminobenzyl sulfide 
• 61010-34-2 3-nitro-4-methoxybenzyl bromide 
• 592542-51-3 4-methoxy-3-nitrophenylmethanesulfonyl acetic acid 
• 22216-44-0 2-(4-methoxy-3-nitrobenzylthio)acetic acid 

Downstream Products

• 592542-59-1 (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic acid 
• 592542-78-4 (E)-2,4,6-trimethoxystyryl-3-(acetamido)-4-methoxybenzylsulfone 
• 592543-08-3 (E)-3-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)propanoic acid 
• 592542-82-0 (E)-2-(5-(2,4,6-trimethoxystyrylsulfonylmethyl)-2-methoxyphenylamino)-propanoic acid 
• 1330633-99-2 (E)-2'',2''-difluoro-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetic acid 
• 1330634-00-8 (E)-3'',3'',3''-trifluoro-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)propanoic acid 
• 1009990-14-0 (E)-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)-methyl)phenylamino)-2-methylpropanoic acid 
• 851799-51-4 (E)-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)-2-phenylacetic acid 
• 1330634-01-9 (E)-2-(4''-fluorophenyl)-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetic acid 
• 1330634-02-0 (E)-2-(4''-chlorophenyl)-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetic acid 
• 1330634-03-1 (E)-2-(4''-bromophenyl)-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetic acid 
• 1330634-04-2 (E)-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)-methyl)phenylamino)-2-(4''-methoxyphenyl)acetic acid 
• 1330633-95-8 (E)-methyl 2-(4''-chlorophenyl)-2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)acetate 
• 1330633-89-0 (E)-methyl 3-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)propanoate 

Relevant articles and documents

2,4,6-TRIALKOXYSTRYL ARYL SULFONES, SULFONAMIDES AND CARBOXAMIDES, AND METHODS OF PREPARATION AND USE

Compounds according to Formula (I) are provided and salts thereof, wherein R1, R2, R33, R4, R5, R6, R13, A, X and Y are as defined herein. Methods for preparing compounds of Form

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.

FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES

Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell prolif